Two decades ago, our laboratory performed its first vaccine study using CEA, including a phase I trial of cancer immunotherapy using CEA peptide-pulsed DCs and basic research on DC vaccine therapy with the transduced CEA gene using a CEA transgenic mouse model3,4,21. Here, CEACAM5 is linked to cancer.